Literature DB >> 26614095

Performing Survival Analyses in the Presence of Competing Risks: A Clinical Example in Older Breast Cancer Patients.

Nienke A de Glas1, Mandy Kiderlen1, Jan P Vandenbroucke, Anton J M de Craen, Johanneke E A Portielje, Cornelis J H van de Velde, Gerrit-Jan Liefers, Esther Bastiaannet, Saskia Le Cessie.   

Abstract

An important consideration in studies that use cause-specific endpoints such as cancer-specific survival or disease recurrence is that risk of dying from another cause before experiencing the event of interest is generally much higher in older patients. Such competing events are of major importance in the design and analysis of studies with older patients, as a patient who dies from another cause before the event of interest cannot reach the endpoint. In this Commentary, we present several clinical examples of research questions in a population-based cohort of older breast cancer patients with a high frequency of competing events and discuss implications of choosing models that deal with competing risks in different ways. We show that in populations with high frequency of competing events, it is important to consider which method is most appropriate to estimate cause-specific endpoints. We demonstrate that when calculating absolute cause-specific risks the Kaplan-Meier method overestimates risk of the event of interest and that the cumulative incidence competing risks (CICR) method, which takes competing risks into account, should be used instead. Two approaches are commonly used to model the association between prognostic factors and cause-specific survival: the Cox proportional hazards model and the Fine and Gray model. We discuss both models and show that in etiologic research the Cox Proportional Hazards model is recommended, while in predictive research the Fine and Gray model is often more appropriate. In conclusion, in studies with cause-specific endpoints in populations with a high frequency of competing events, researchers should carefully choose the most appropriate statistical method to prevent incorrect interpretation of results.
© The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Year:  2015        PMID: 26614095     DOI: 10.1093/jnci/djv366

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  28 in total

1.  Competing nomograms help in the selection of elderly patients with colon cancer for adjuvant chemotherapy.

Authors:  Dan Li; Chenhan Zhong; Xiujun Tang; Linzhen Yu; Kefeng Ding; Ying Yuan
Journal:  J Cancer Res Clin Oncol       Date:  2018-02-19       Impact factor: 4.553

2.  Accounting for individualized competing mortality risks in estimating postmenopausal breast cancer risk.

Authors:  Mara A Schonberg; Vicky W Li; A Heather Eliassen; Roger B Davis; Andrea Z LaCroix; Ellen P McCarthy; Bernard A Rosner; Rowan T Chlebowski; Susan E Hankinson; Edward R Marcantonio; Long H Ngo
Journal:  Breast Cancer Res Treat       Date:  2016-10-21       Impact factor: 4.872

3.  Impact of Older Age and Comorbidity on Locoregional and Distant Breast Cancer Recurrence: A Large Population-Based Study.

Authors:  Anna Z de Boer; Heleen C van der Hulst; Nienke A de Glas; Perla J Marang-van de Mheen; Sabine Siesling; Linda de Munck; Kelly M de Ligt; Johanneke E A Portielje; Esther Bastiaannet; Gerrit Jan Liefers
Journal:  Oncologist       Date:  2019-09-12

4.  Refining breast cancer prognosis by incorporating age at diagnosis into clinical prognostic staging: introduction of a novel online calculator.

Authors:  Helen M Johnson; William Irish; Nasreen A Vohra; Jan H Wong
Journal:  Breast Cancer Res Treat       Date:  2021-02-20       Impact factor: 4.872

5.  Prognostic value of LODDS in medullary thyroid carcinoma based on competing risk model and propensity score matching analysis.

Authors:  Zhe Xu Cao; Xin Weng; Jiang Sheng Huang; Xia Long
Journal:  Updates Surg       Date:  2022-07-12

6.  Impact of Comorbidities and Age on Cause-Specific Mortality in Postmenopausal Patients with Breast Cancer.

Authors:  Marloes G M Derks; Cornelis J H van de Velde; Daniele Giardiello; Caroline Seynaeve; Hein Putter; Johan W R Nortier; Luc Y Dirix; Esther Bastiaannet; Johanneke E A Portielje; Gerrit-Jan Liefers
Journal:  Oncologist       Date:  2019-01-03

7.  Is Cancer Protective for Subsequent Alzheimer's Disease Risk? Evidence From the Utah Population Database.

Authors:  Heidi A Hanson; Kevin P Horn; Kelli M Rasmussen; John M Hoffman; Ken R Smith
Journal:  J Gerontol B Psychol Sci Soc Sci       Date:  2017-10-01       Impact factor: 4.077

8.  Prevalence, Outcome, and Management of Risk Factors in Patients With Breast Cancer With Peripheral Arterial Disease: A Tertiary Cancer Center's Experience.

Authors:  Yolanda Bryce; Richard Bourguillon; Juan Camacho Vazquez; Etay Ziv; Daehee Kim; Ernesto Santos Martin
Journal:  Clin Breast Cancer       Date:  2020-12-30       Impact factor: 3.078

9.  Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial.

Authors:  Hartmut Döhner; Argiris Symeonidis; Dries Deeren; Judit Demeter; Miguel A Sanz; Achilles Anagnostopoulos; Jordi Esteve; Walter Fiedler; Kimmo Porkka; Hee-Je Kim; Je-Hwan Lee; Kensuke Usuki; Stefano D'Ardia; Chul Won Jung; Olga Salamero; Heinz-August Horst; Christian Recher; Philippe Rousselot; Irwindeep Sandhu; Koen Theunissen; Felicitas Thol; Konstanze Döhner; Veronica Teleanu; Daniel J DeAngelo; Tomoki Naoe; Mikkael A Sekeres; Valerie Belsack; Miaomiao Ge; Tillmann Taube; Oliver G Ottmann
Journal:  Hemasphere       Date:  2021-08-02

10.  Predictors of Lymph Node Metastasis in Siewert Type II T1 Adenocarcinoma of the Esophagogastric Junction: A Population-Based Study.

Authors:  Liubo Chen; Kejun Tang; Sihan Wang; Dongdong Chen; Kefeng Ding
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.